Drug Search Results
More Filters [+]

Estradiol valerate

Alternative Names: estradiol valerate, progynova, oestradiol valerate, delestrogen, ditate-ds
Latest Update: 2024-11-25
Latest Update Note: Clinical Trial Update

Product Description

Estradiol Valerate (also known as E2V) is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Estradiol-valerate)

Mechanisms of Action: ER Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Estradiol valerate

Countries in Clinic: India

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Prostate Cancer

Phase 1: Acute Respiratory Distress Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STAMPEDE

P3

Unknown status

Prostate Cancer

2030-12-04

HP8833-01

P1

Completed

Acute Respiratory Distress Syndrome

2022-03-22

53%

HP8833-01

P1

Completed

Acute Respiratory Distress Syndrome

2022-03-22

53%

Recent News Events